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 ABBREVIATION 
 
CVD - cardio vascular disease 
OPG - osteoprotegerin 
NF-κB - nuclear factor – kappa B 
RANK - receptor activator of nuclear factor - kappa 
RANKL - receptor activator of nuclear factor – kappa ligand 
TNF-α - tumour necrosis factor - α   
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IL-1 - interleukin -1  
PDGF - platelet derived growth factor 
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MMP - matrix metallo proteinases 
  
ROS - reactive oxygen species  
NO - nitric oxide 
ENOS - endothelial nitric oxide synthase 
DAG - di acyl glycerol 
DM - diabetes mellitus 
EC - endothelial cells 
SMC - smooth muscle cells 
VSMC - vascular smooth muscle cells  
MCP-1 - monocyte chemoattractant protein - 1 
M-CSF - macrophage – colony stimulating factor 
ECM - extra cellular matrix 
CHD - coronary heart disease 
IHD - ischemic heart disease 
AGE - advanced glycation end products 
CK - creatine kinase 
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NK Cells - natural killer cells 
VEGF - vascular endothelial growth factor 
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INTRODUCTION 
 
 Coronary artery disease (CAD) is held as the most common cause of 
mortality and morbidity in diabetics (prevalence being 10 – 20% as compared to 
non diabetics being 1-4%), usually advanced at the time of diagnosis and an 
unfavourable prognosis. (1) 
 
 CAD tops the list of mortality despite the hold of new pharmacologic 
approaches. Myocardial infarction (MI) is the first presentation of CAD. Silent MI 
is myocardial ischemia, in the absence of chest pain or an angina analogue. Most 
of these episodes occur during minimal or no physical exertion. Myocardial 
infarction is a major consequence of atherosclerosis and the co-occurrence of 
diabetes accelerates its incidence. Atherosclerosis is an inflammatory disease, 
beginning with a fatty streak and progressing to an atheromatous plaque. The 
plaque ruptures and complicates with subsequent calcification of the vessel 
wall.(2) 
 
 Although investigations, like coronary artery calcium score and myocardial 
perfusion imaging  have been developed, a biomarker which is specific enough to 
identify the patients at risk would be invaluable.(3) 
 
 Osteoprotegerin (OPG), a glycoprotein, which is concerned with 
remodelling of bone along with  modulation ofvascular, immune and skeletal 
systems, unfolds as an independent biomarker of cardiovascular disease.(4,5) 
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 It is not only involved with the presence of CAD but also has been shown 
to correlate with its severity.(6) 
 
 OPG is being incriminated in infirmities like diabetes & poor glycaemic 
control.(7) 
 
 The interconnection between the circulating OPG levels and cardiovascular 
(CV) complications has been focussed in this study, with particular emphasis on 
patients with diabetes. OPG level was found to be increased in both patients with 
diabetes and diabetic patients enduring MI than the healthy controls. 
 
  
Review of Literature 
  
3 
 
REVIEW OF LITERATURE 
 
ATHEROSCLEROSIS 
 Atherosclerosis is characterised by lesions called ‘atheroma’ or 
‘atheromatous or fibro-fatty plaques’ that protrudes to occlude the lumen and 
enfeeble the underlying media. Atherosclerosis remains globally distributed and 
contributes to approximately half of all the deaths and is found to produce serious 
morbidity than any infirmity.(8) 
 
Natural antiquity and outcome of atherosclerotic lesions: 
 The American heart association classifies the lesions in to six types; 
beginning with foam cells through the stages of fatty streaks, atheromas and fibro-
atheromas to the complicated lesions. First, the lesion prone site is filled by 
macrophages hampered with lipid - Type I. Lesions with fatty streaks - Type II. 
Extracellular puddles of lipid along with the lesions mentioned in second type are 
classified under Type III. Atheromas are grouped under Type IV. The fibro-
atheromatic lesions under Type V. Type VI lesions are complicated with 
hematoma-haemorrhage or thrombus.(9,10) 
 
 Fatty streaks are the earliest lesions and are composed of lipid loaded 
foam cells. They are not heaped up lesions and hence do not cause any hindrance 
to the blood flow. They are inclusive of T lymphocytes and, to a smaller extent of 
extracellular lipid. Coronary fatty streaks set about to organise right from the 
adolescence at sites which are exposed to turbulent blood flow. They are related to 
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risk factors of atherosclerosis like serum lipoprotein cholesterol levels & smoking 
in adults. Evidences support the concept of evolution of fatty streaks in to plaques 
that become advanced lesions.(11) 
 
 Atheromatous plaques are elevated lesions of intima that develop 
primarily in elastic arteries (e.g., aorta & carotid), large and medium sized 
muscular arteries (e.g., coronary arteries). Symptomatic disease often involves the 
arteries of heart, brain, kidneys and lower extremities. Myocardial infarction is a 
major consequence of atherosclerosis.(12) 
 
Morphology of atherosclerotic plaques:  
 Atheromas are focal lesions in intima with a soft core of lipids covered by 
a fibrous cap. The plaque constitutes of; 
i) Cells – smooth muscle cells (SMC), macrophages, leukocytes 
ii) Extracellular matrix (ECM) – collagen, elastic fibres, proteoglycans 
iii) Intra and extracellular lipids. 
 
 Plaques have a ‘fibrous cap’ which contains SMC and ECM. The place 
where fibrous cap encounters the vessel wall is called ‘shoulder’ which is cellular 
and consists of macrophages and T-cells along with SMC. The ‘necrotic core’ is 
seen deep to the fibrous cap and has lipids like cholesterol and cholesterol esters, 
necrotic debris, lipid laden macrophages (foam cells), SMC, fibrin and variably 
organised thrombus and plasma proteins. In the periphery of these lesions, occur 
neovascularisation as shown in fig.1. The media layer below this lesion is 
fibrosed secondary to the SMC atrophy and loss. Typically atheromas have 
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abundant lipid but fibrous plaques composed of SMC and fibrous tissue are also 
present. Plaques continue to enlarge through degeneration of cells, ECM 
remodelling and thrombus organization. Moreover atheromas often undergo 
calcification which appear to be at an increased risk of coronary events.(2,13,14) 
 
Fig 1: The basic structure of atheromatous plaque 
 
(Courtesy: Robbins textbook of Pathology) 
 
Pathogenesis:  
 Two hypotheses for atherogenesis have been emphasized. First hypothesis 
highlights the cellular proliferation in intima and the other points out the 
organization and repetitive growth of thrombi. The contemporary view of 
pathogenesis incorporates the theories and risk factors. This concept is called 
“response to injury hypothesis” which reckons atherosclerosis as a chronic 
inflammatory response of the arterial wall initiated by injury to endothelium. The 
progression of the lesion is perpetuated by modified lipoproteins, monocyte - 
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derived macrophages, T lymphocytes and the normal cellular constituents of 
arterial wall.(15) 
 
Response to injury hypothesis:  
 Chronic endothelial injury with concomitant endothelial dysfunction 
leading to increased permeability, leukocyte adhesion and thrombotic 
potential. 
 Accumulation of lipoproteins mainly LDL with high cholesterol content. 
 Modification of those lipoproteins by oxidation. 
 Adhesion of monocytes to endothelium followed by their migration in to 
intima and transformation in to macrophages and foam cells. 
 Adhesion of platelets. 
  Release of factors from activated platelets, macrophages that cause 
migration of SMCs from media to intima. 
 Proliferation of SMCs and synthesis of ECM causing the accumulation 
of collagen and proteoglycans. 
 Enhanced accumulation of lipids within cells (macrophages and SMC) 
and extracellularly as shown in fig. 2.(15–17) 
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Fig 2: Evolution of arterial 
wall changes in response to 
injury hypothesis. 
1. Normal 
2. Endothelial injury with 
adhesion of monocytes 
and platelets 
3. Migration of monocytes 
and SMC to intima 
4. SMC proliferation in the 
intima 
5. Well developed plaque  
(Courtesy: Robbins Textbook 
of Pathology) 
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The role of endothelial injury:  
 Chronic or repetitive endothelial injury is the bedrock of this hypothesis 
and the potential culprits include circulating toxins of cigarette smoke, 
homocysteine, infections, inflammatory cytokines and immune injuries. 
Inflammatory cytokines stimulate the expression of endothelial genes that 
promote atherosclerosis. But the two main determinants are hemodynamic 
disturbances that work in coordination with hypercholesterolemia. The 
hemodynamic effects are well defined at the ostia of vessels arising from aorta, 
branch points and posterior wall of abdominal aorta, where there is turbulent flow 
of blood and low sheer stress.  
 
The role of inflammation:  
 The inflammatory mechanism initiates, progresses and complicates the 
lesions. The normal endothelium does not allow the binding of white blood cells. 
But in atherosclerosis, they express selective adhesion molecules that bind 
leukocytes. One such molecule is VCAM-I (vascular cell adhesion molecule -1) 
that bind precisely to monocytes and T-cells.(18,19) After adhering to endothelium, 
monocytes migrate to intima which is mediated by chemokines and transform in 
to macrophages and engulf oxidised LDL. Although this process appears to be 
protective as they remove potentially harmful lipid particles, accumulation leads 
to progression of lesion. Macrophages secrete inflammatory cytokines like 
interleukin – 1 (IL-1), tumour necrosis factor (TNF-α) and monocyte chemo-
attractant protein (MCP-1), which recruits more leukocytes in to plaque. These 
macrophages produce toxic oxygen species that oxidise LDL in the lesions and 
9 
 
elaborate growth factors that contribute to SMC proliferation. T cells recruited by 
chemokines harmonise with macrophages to produce a picture similar to chronic 
inflammation. The activated leukocytes and intrinsic arterial cells release 
fibrogenic mediators that promote SMC replication and elaboration of dense ECM 
by these cells.(20–22) 
 
The role of lipids: 
The lipoprotein abnormalities associated are  
1. Increased LDL cholesterol levels 
2. Decreased HDL cholesterol levels 
3. Increased levels of Lp(a) 
 
The mechanisms by which hyperlipidemia contributes to atherogenesis include: 
 Chronic hyperlipidemia, particularly hypercholesterolemia directly impairs 
EC function through increased production of oxygen free radicals that 
deactivate nitric oxide, the major vasodilator. 
 Lipoproteins accumulate within the intima at the regions of increased 
endothelial permeability. 
 Chemical change of lipids by the free radicals producing oxidised LDL. 
Oxidised LDL engulfed by macrophages produce foam cells which recruits 
more monocytes in the lesion, stimulating the release of growth factors & 
cytokines that is cytotoxic to EC and SMCs.(23,24) 
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The role of smooth muscle cells:  
 The SMCs migrate from the media to intima, where they replicate and 
deposit ECM components causing maturation of the fatty streak in to a fibro-
fatty atheroma aiding in the progression of the atherosclerotic lesion. The 
growth factors implicated in the process are platelet derived growth factor 
(PDGF) from the platelets adhered to the injured endothelial cells, fibroblast 
growth factor (FGF), interleukin-1, IL-18, IFN-γ and TGF-α.  SMC can also 
take up modified lipids to form foam cells. They also synthesize extracellular 
matrix components mainly collagen which stabilizes the plaques as shown in 
fig.3. (2,25,26) 
 
Fig 3:  Schematic diagram of hypothetical sequence of cellular 
interactions in atherosclerosis. 
 
(Courtesy: Robbins Textbook of Pathology) 
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RISK FACTORS FOR MI: 
CONTROLLABLE NON-MODIFIABLE 
Hyperlipidemia, Hypertension Increasing age, family history, obesity 
Cigarette smoking, Diabetes Male gender, Genetic abnormalities 
Alcohol, Trans fat intake Physical inactivity, Type A personality 
Lipoprotein Lp(a) Post menopausal women 
 
Age:   
 Age has a predominant role as the death rates increase with each decade. 
Atherosclerosis is not evident until middle age or later, when the arterial lesions 
precipitate organ injury. The incidence increases five fold in the middle age.(27) 
 
Sex:  
 Males are much prone to atherosclerosis than pre-menopausal women, 
unless they are predisposed to diabetes, hyperlipidemia or severe hypertension.  
The incidence is equal in males and females due to the fall in oestrogen levels 
after menopause.(28) 
 
Genetics:  
 The familial predisposition to atherosclerosis and ischemic heart disease is 
mostly polygenic. The genetic propensity to diabetes and hypertension relates to 
atherosclerosis and less commonly the hereditary derangements of lipoprotein 
metabolism.(29) 
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Non genetic risk factors:  
 Diet, lifestyle, cigarette smoking and personal habits are potentially 
reversible risk factors.(30) 
 
Hyperlipidemia:  
 High dietary intake of cholesterol and saturated fats like those present in 
egg yolk, animal fats and butter raise the plasma cholesterol levels. Omega 3 fatty 
acids are beneficial over trans fat produced by hydrogenation of PUFA. Exercise 
raises the HDL levels whereas obesity and smoking lower it. Drugs like statins 
lower circulating cholesterol levels by indirectly inhibiting HMG CoA reductase 
enzyme required for cholesterol synthesis.(31) 
 
Hypertension:  
 It is a major risk factor in all age groups. Both systolic and diastolic blood 
pressure are important in increasing risk. Anti – hypertensives reduce the risk of 
MI.(32) 
 
Diabetes:  
 It induces hypercholesterolemia and markedly predisposes to 
atherosclerosis. The incidence of myocardial infarction is twice high in diabetics 
than non diabetics.(4)(34,35) The morbidity accompanying diabetes involves 
macrovascular and microvascular diseases, the macrovascular disease being 
accelerated atherosclerosis resulting in the increased risk of myocardial infarction. 
This is thought to be due to metabolic derangements, mainly hyperglycaemia.  
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At least four distinct metabolic pathways appear to be involved in the 
pathogenesis, although the primacy of any one has not been established.  
 
1. Formation of Advanced Glycation End products (AGE): 
 The AGEs are formed by the non-enzymatic reactions between 
intracellular glucose – derived dicarbonyl precursors (glyoxal, methylglyoxal & 3-
deoxy glucasone) and the amino group of the intra & extracellular proteins. These 
products have detrimental effects on the extracellular matrix and endothelium. 
 
 On the extracellular matrix: AGEs produce cross-linking between the 
polypeptides of ECM (collagen & laminin) that causes abnormal matrix – 
matrix and matrix – cell interactions. For example, the cross-linking between 
the type I collagen molecules in vessels results in decrease of their elasticity, 
which predisposes to sheer stress and endothelial injury. These AGE cross-
linked proteins are resistant to proteolytic digestion and their deposition in the 
vessels are enhanced. AGE-modified matrix components trap non-glycated 
plasma or interstitial proteins. Trapping LDL in the vessels retards its efflux 
from the vessel wall and enhances the deposition of cholesterol in intima, 
hence accelerating atherosclerosis. 
 
 Circulating plasma proteins modified by addition of AGE residues finally 
bind to AGE receptors on cells like endothelial cells and macrophages. This 
binding results in activation and nuclear translocation of plieotrophic factor 
NF-κB. The effects of activating this pathway include 1) generating a number 
of cytokines, growth factors and pro-inflammatory molecules like insulin-like 
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growth factor-1, TGF-β, PDGF & VEGF; 2) increased endothelial 
permeability;   3) increased procoagulant activity on EC and macrophages by 
induction of thrombomodulin and tissue factor; and 4) enhanced proliferation 
and synthesis of extracellular matrix by fibroblasts and SMCs as shown in 
fig.4.(36) 
 
Fig.4:  Effects of advanced glycation end (AGE) products 
 
  
ON INTRACELLULAR & PLASMA PROTEINS
Generation of reactive oxygen species And NF-κb activation
Target cells respond by 1. Cytokines & GF secretion, 2. Induction of pro-
coagulant activity, 3. Increased vascular permeability, 4. Enhanced ECM 
production
ON ECM: ABNORMAL MATRIX-MATRIX & MATRIX-CELL 
INTERACTIONS
1.Cross - linking between type I collagen- decreasing elasticity of vessels
2. Trapping of non-glycated proteins & resistance to proteolytic degradation
FORMATION OF ADVANCED GLYCATION END PRODUCTS 
(AGE)
Glucose- derived dicarbonyl 
precursors
Amino group of intra and 
extracellular proteins
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2. Activation of Protein kinase C:  
Intracellular hyperglycaemia stimulates the de novo synthesis of diacyl 
glycerol (DAG) from glycolytic intermediates which acts as a second messenger. 
DAG activates protein kinase C and its downstream effects are the following as 
shown in fig.5. (37) 
 
Fig.5:Cascade of events following the activation of Protein kinase C 
 
 
3. Intracellular hyperglycaemia activating polyol pathway: 
 In tissues that do not require insulin for glucose transport, hyperglycaemia 
causes an increased intracellular glucose which is metabolised by the enzyme 
aldose reductase to sorbitol, a polyol, and finally fructose. This process requires 
Intracellular 
Hyperglycemia,   
↑DAG
Activation of PK -
C and further NF-
κB
↑Pro-
angiogenic 
VEGF
NEO-
VASCULAR
-ISATION
↑ Endothelin-1 
and  ↓Nitric 
oxide
VASO
CONSTRIC-
TION
↑Pro-
fibrogenic 
TGF-β
ECM 
DEPOSITION
↑Pro-
coagulant -
PAI-1
VASO-
OCCLUSIV
E EPISODES
↑Pro-
inflammatory 
cytokines by 
endothelium
16 
 
intracellular NADPH as a cofactor. NADPH is also required by enzyme 
glutathione reductase to regenerate reduced glutathione (GSH), which is an anti-
oxidant. A reduction in GSH levels increases the susceptibility to oxidative stress. 
As a matter of fact, prolonged hyperglycaemia leads to progressive depletion of 
intracellular NADPH by aldose reductase causing an undermining of GSH 
regeneration as shown in fig.6.(38) 
 
Fig.6: Prolonged hyperglycemia causing activation of polyol pathway 
 
 
 
 
 
 
 
 
 
4. Activation of hexosamine pathway: 
 Hyperglycaemia leads to the conversion of glucose to Fructose-6-
phosphate and stimulates the hexosamine pathway which produces Glucosamine 
6-phosphate. This reaction is catalysed by glutamine:fructose 6-phosphate 
amidotransferase (GFAT). Glucosamine 6-phosphate has shown to be converted 
to UDP N-acetyl glucosamine, that will bind to the serine and threonine moieties 
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on transcription factors causing an aggravation of oxidative stress and the release 
of cytokines like TGF-β as shown in fig.7.(39,40) 
 
Fig.7: Stream of events in hexosamine pathway, in the setting of 
hyperglycaemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morphology of diabetic Macrovascular disease:  
 The hallmark of this condition is accelerated atherosclerosis of large and 
medium sized arteries. Hyaline arteriosclerosis is more prevalent and severe in 
diabetics.(41) It takes the form of an amorphous hyaline narrowing the vessel 
lumen and consequently leading to MI which is an irreversible damage to 
myocardium.(33) 
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Fig. 8: Pathogenesis of accelerated atherosclerosis in diabetes 
(Courtesy: Davidson’s Principle and Practice of Medicine) 
 
MYOCARDIAL INFARCTION:  
 It is mostly due to occlusion of coronary arteries stenosed by 
atherosclerosis. The artery most commonly affected is left anterior descending 
artery, followed by right coronary artery and left circumflex artery. In case of 
acute coronary occlusion, blood flow ceases but a small amount of collateral flow 
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salvages the tissues from surrounding vessels. That area of muscle cannot sustain 
its function and is termed an ‘infarct’. The cardiac muscle requires 1.3 mL of 
oxygen/100 grams of tissue/ minute and when the imbalance between oxygen 
supply and demand is only minimal, cell death is either minimal or absent but a 
part of myocardium becomes temporarily non functional. When the imbalance is 
high, cell death is inevitable and the enclosing muscle fibres too ensue infarction. 
Development of collaterals may restore some amount of function but fibrous 
tissue replaces the dead tissue leading to the loss of contractile ability.  
 
Biochemical consequences of ischemia: 
 Ischemia depending on its severity causes anoxia of various grades. The 
consequences of anoxia are the following: 
 
1. Aerobic metabolism switches over to anaerobic metabolism. Hence, ATP 
which had been majorly produced by oxidative phosphorylation is reduced. 
As a consequence intracellular sodium and calcium are raised due to the 
following reasons: 
 
a. The reduced myocardial ATP interferes with the trans-sarcolemmal 
Na+-K+ exchange which in turn elevates sodium and decreases 
potassium intracellulary.  
b. Increased calcium due to reduced uptake of calcium by sarcoplasmic 
reticulum, decreased extrusion from cells and enhancement of sodium 
channel. This causes an increased load on mitochondria which 
depresses ATP synthesis and augments ATP utilization. 
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2. Flow of substrates in to myocardium and the removal of metabolic 
products from the cell are greatly reduced. This causes an increase in the 
intracellular osmotic pressure causing cell damage.  
 
 The above factors cause depletion of ATP, lactic acid accumulation and 
severe acidosis hence marked reduction in the contractile force of the cardiac cell. 
The accumulated lactic acid and hydrogen ions inhibit glycolysis at the level of 
glyceraldehyde-3-phosphate dehydrogenase which reduces the level of oxidised 
NAD. This leads to the loss of sarcolemmal integrity that liberates cellular 
constituents in to circulation which are: 
 
1. Muscle proteins: myoglobin and contractile protein myosin 
2. Regulatory proteins: tropomyosin, troponin T, troponin C & troponin I 
3. Cytoplasmic enzymes: creatine kinase (CK), lactate dehydrogenase (LDH) 
& aspartate amino transferase (AST). 
 
NOVEL BIOMARKERS:  
1. Chromogranin 
2. Galactin-3 
3. Adiponectin 
4. Growth differentiation factor  15 
5. Osteoprotegerin(42) 
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OSTEOPROTEGERIN: 
 Osteoprotegerin was discovered concomitantly by two different research 
cohorts in 1997. Simon et al. found that it was a new member of tumour necrosis 
factor (TNF) receptor superfamily while working on the foetal rat intestine 
complementary deoxyribonucleic acid (c – DNA) sequencing project and named it 
Osteoprotegerin due to its protective effects on bone.(43) Simultaneously, Tsuda et 
al. found a novel protein which was found to inhibit the activity of osteoclasts and 
hence named it “Osteoclastogenesis Inhibitory Factor” (OCIF).(44) Later on 
Yasuda et al. promulgated that these separate findings denoted the same 
molecule(45). 
 
 Osteoprotegerin is a cytokine of the TNF - receptor superfamily and 
termed as TNF receptor superfamily member 11B (TNFRS11B).(46) The American 
society of bone and mineral research committee have decided to use the term 
‘Osteoprotegerin’ due to its protective effects on the bone.(43,47) 
 
 The OPG gene is a single copy gene cluster located on the chromosome 8 
(8q24) and contains 5 exons over 29 kb. Northern blotting produced three 
messenger RNA transcripts of 2.4, 4.2 and 6.4 kb of which 2.4 kb constitutes the 
major transcript. 
 
STRUCTURE: 
 Osteoprotegerin is a secretory glycoprotein present as a monomer with 401 
amino acids weighing 60 kDa. It has got seven structural domains. 
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i. Domains 1 – 4 have pseudorepeats which are rich in cysteine residues, 
structurally related to TNF receptor family; located in the N-terminal. It is 
essential for the inhibition of osteoclastogenesis. 
ii. Domains 5 – 6are the death domains; located in carboxy – terminal end. 
They contain apoptosis - mediating death domain homologous regions. 
iii. Domain 7 is a heparin binding site; located in the carboxy – terminal. It is 
capable of interacting with various proteoglycans and free cysteine 
residues necessary to form disulfide bonds and dimers as shown in fig.9.(48) 
Fig 9: Structure of Osteoprotegerin 
 
(Courtesy: Michiyo Kobayashi-Sakamoto – Integrative Molecular Medicine) 
 
 OPG is initially secreted as a monomer which undergoes dimerization at 
the cysteine 400 residue to form a disulfide – linked homodimer (the mature 
form). Thus, the homodimer form is more active and is necessary to elicit the full 
biological activity.  The affinity of OPG dimer for RANKL is much higher than 
the monomeric form. (49,50). It is involved in suppressing the formation of 
osteoclasts by preventing the binding of RANKL to RANK on the osteoclast 
precursor cells.(51,52) “The model was built based on the three-dimensional 
Domains 
Homologous region 
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structures of the TNF--TNF receptor 1 complex, TRAIL-death receptor 5 
complex and Fas-Fas ligand complex. The receptor complex is shown as a 
spherical model in fig.10. OPG is coloured according to atom (green, C; blue, N; 
red, O; orange, S) and, for clarity, the ligand is shown in orange. The critical loop 
OP3-4 is shown in cyan. 
 
Fig. 10: Three-dimensional model of the OPG/RANKL complex 
 
(Courtesy: Deborah J. Heath, Karin Vanderkerken, Xin Cheng, et al., Cancer Res 
2007;67:202-208) 
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OPG/ RANK/RANKL PATHWAY: 
 Osteoblasts and osteoclasts together play a significant role in maintaining 
the balance between finely balanced dynamics of bone formation and resorption. 
Osteoblasts are crucial for the differentiation and proliferation of osteoclasts.  
 
The RANK is a homotrimeric transmembrane protein made of 616 amino 
acids including a signal peptide of 28 amino acids, short transmembrane domain 
of 21 amino acids intracellular domain of 383 amino acids at the carboxy – 
terminal. It is expressed on osteoclast precursors, mature osteoclasts, dendritic 
cells, fibroblasts, articular chondrocytes and some cancer cells like breast and 
prostate carcinomas. RANKL is expressed in osteoblasts, stromal cells and  
T lymphocytes.  
 
When RANK binds to its ligand (RANKL), it assembles as an effective 
trimeric receptor and regulates a spectrum of signals like cell differentiation, 
function and survival, among other functional osteoblasts. 
 
 The interaction of RANKL – RANK leads to the activation of nuclear 
factor – κB that occurs by the degradation of the protein Iκ-B by Iκ-B kinase. The 
degradation of this protein releases the nuclear factor - κB (NF- κB) complex, 
which initiates the intracellular signalling cascades causing transcription of genes 
responsible for formation, differentiation and activation of osteoclasts resulting in 
bone resorption.  
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OPG is expressed in the endothelial cells, vascular smooth muscle cells and 
osteoblasts. It acts as a soluble decoy receptor for RANKL. OPG competes with 
RANK and inhibits RANKL – RANK interactions thereby inhibiting the bone 
resorption as shown in fig.11.(53,54) 
 
Fig. 11: Osteoprotegerin (OPG) Neutralises the Effects of RANK Ligand 
 
 
(Courtesy: Boyle WJ et al. Nature 2003; 423: 337-342) 
 
 Within the endothelial cells, OPG is found in association with von 
Willibrand factor within secretory granules called Weibel – Palade bodies. During 
stress / inflammation release of TNF-α or IL-1β in vitro causes the OPG-von 
Willibrand complex to be secreted in to surrounding growth medium. This complex 
is also noted in the human serum, showing that endothelial cells activated by pro-
inflammatory cytokines as one of the possible causes of circulating OPG in patients 
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with active atherosclerosis. OPG has been demonstrated in normal arteries but 
RANK, RANKL and osteoclasts have been identified in the calcified arteries only. 
 
OPG also seems to play a vital role in cell survival through its interaction 
with another member of TNF superfamily - tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL), a homotrimer (55). TRAIL is expressed as a 
type 2 transmembrane protein. The extracellular domain of this protein is cleaved 
proteolytically from the cell surface and acts a soluble cytokine. TRAIL acts by 
binding to 4 receptors; two of these (TRAIL receptor 1/ death receptor 4 and 
TRAIL receptor 2/ death receptor 5) contain cytoplasmic sequences homologous 
to the death domains of Fas and TNF receptor – 1, and are able to mediate 
apoptosis via caspase activation pathways. TRAIL receptors 3 and 4, along with 
OPG, are decoy receptors for TRAIL. Endothelial cells and vascular smooth 
muscle cells express TRAIL receptors 1 & 2, but recombinant TRAIL conversely 
promotes proliferation and survival of cells through the Akt / PKB (protein kinase 
B) and extracellular signal–regulated kinase/ mitogen-activated protein kinase 
(MAP-kinase) pathways.(3,49) TRAIL has been found to decrease in patients with 
MI(55,56). 
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ROLE OF OPG IN ATHEROSCLEROSIS AND VASCULAR 
CALCIFICATION: 
Selective deletion of OPG in mice resulted in early onset and severe 
osteoporosis with significant medial calcification of aorta and renal arteries. These 
arteries are also the sites of endogenous OPG expression in normal arteries, 
raising the possibility of its protective role. 
 
 Checking out the protective role of OPG in vascular calcification, Mine et 
al. observed that transgenic expression of OPG in OPG knock-out mice prevents 
the onset of arterial calcification but exogenous administration of recombinant 
OPG did not reverse the aortic calcification underlining the significance of timing 
of OPG delivery.(57) 
 
 The cells of vascular origin that can be suspected of osteogenic phenotypic 
transformation are adventitial myofibroblasts, pericyte-like calcifying vascular 
cells and vascular smooth muscle cells (VSMCs). In the light of the considerable 
role of VSMC in atherosclerosis and calcification, VSMC and endothelial cells 
are credible for the increased circulating levels of OPG in cardiovascular diseases. 
 
A few potential reasons for the role of OPG in preventing the arterial calcification 
are: 
i. RANKL is expressed robustly in the extracellular matrix of vessels with 
calcified plaques and has been shown to promote osteogenic phenotypic 
transformation of VSMCs via the bone morphogenic protein-4 (BMP-4) 
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pathway and alkaline phosphatase activity. OPG being the decoy receptor 
for RANKL inhibits this process thereby inhibiting the calcification. 
ii. Endothelial dysfunction causes the increased translocation of inflammatory 
cells from lumen to intima and increased production of pro-inflammatory 
cytokines like TNF-α and Interferon-γ resulting in the initiation of 
calcification and also upregulation of OPG expression, possibly a counter-
protective action. 
iii. TRAIL is known to induce apoptosis of ECs and VSMCs in atherosclerotic 
plaques but binding of TRAIL to its decoy receptor OPG inhibits the pro-
apoptotic action and reducing the calcification.(57) 
 
 Contradictory to the protective role of OPG in animal models, there seems 
to be a distinct relation between OPG and severity of atherosclerosis in human 
studies. 
 
Role of OPG and RANKL in the pathogenesis of atherosclerosis: 
 When human umbilical vein endothelial cells were incubated with 
increasing concentrations of OPG and TNF-α in vitro, OPG was found to show a 
linear increase in the expression of adhesion molecules like E-selectin, vascular 
cell adhesion molecule and intercellular adhesion molecule.(5) It was found that 
OPG acts to sensitize endothelial cells to TNF-α by up-regulating angiopoietin-2 
to enhance endothelial adhesion of monocytes. This causes an increased binding 
of monocytes to endothelial cells before migrating in to intima, a significant step 
in the pathogenesis of atherosclerosis.(58,59) 
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 Venuraju et al. suggests the association of RANKL and its receptor in 
atherosclerosis with vascular calcification. In the vessel wall, RANKL is 
expressed on EC, smooth muscle cells, T lymphocytes and mast cells and its 
receptor RANK being expressed on the surfaces of macrophages and dendritic 
cells. The mechanism by which OPG mediates atherosclerosis and plaque 
instability is shown in fig.12.(3,60,61) 
 
Fig.12 : Role of OPG / RANKL in Atherosclerosis & Plaque Stability 
 
 
(Courtesy: Venuraju et al. JACC – Vol 55, No. 19, 2010) 
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 In the presence of pro-inflammatory cytokines, the expression of OPG is 
up-regulated in endothelial cells, which in turn increases the expression of 
endothelial adhesion molecules, aiding in the chemotaxis. 
 The inflammatory cells up-regulate the expression of RANKL and form 
vascular smooth muscle cells. 
 Matrix metalloproteinase activity is increased. 
 Increased MMP activity leads to degradation of extracellular matrix and 
reduced thickness of fibrous cap, the erosion of which leads to thrombus 
formation (3). 
 
Clinical utility of OPG as biomarker:  
 In view of association of OPG with prevalence and severity of CAD, it can 
be developed as biomarker and therapeutic target for vascular disease.(62) 
 
 Atherogenesis is an intense inflammatory process having both immune and 
vascular cells involved. The anatomic structure of a plaque which is localised in 
intima contains foam cells, immune cells (T cells, B cells, NK cells, mast cells & 
dendritic cells), vascular endothelial cells and smooth muscle cells, around a core 
of lipids, ECM and lipid rich debris of dead cells. The lipid core is covered by a 
fibrous cap – a layer of smooth muscle cells and is separated from the blood 
stream by a layer of endothelial cells. These cells secrete cytokines, proteases and 
pro-thrombotic factors. The mediators and the plasticity of these cells are 
responsible for plaque instability and carry a high risk of fibrous cap disruption 
with subsequent ischemic and thrombotic events like arterial occlusion and 
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embolism. Plaque calcification is strongly associated with plaque rupture and in 
fact, the degree of calcification fosters a number of interfaces between rigid and 
distensible portions of plaque until the point of rupture. This conveys that there is 
dystrophic calcification in the fibrous cap rather than a fully formed bone 
histologically, which is associated with an increased risk of rupture. Monocytes, 
dendritic cells and smooth muscle cells, controlled by cytokines, play a crucial 
role in calcification due to their retained capability to differentiate in to osteoblast 
and osteoclast like cells.(63) 
 
 Previously it was considered that calcification was a passive deposition of 
calcium but recent studies suggest that it is a result of arterial osteogenesis. 
Doherty et al. identified two types of calcification –medial and intimal, which are 
different entities but are not necessarily separated. Medial calcification occurs 
independent of atherosclerosis and is observed with Monckeberg’s sclerosis, 
hypervitaminosis D, end stage renal failure disease (ESRD) and diabetes mellitus. 
In ESRD, an association of arterial calcification, increased serum phosphorous 
and ion products [Ca2+ * PO43- ] was shown. In diabetes, Edmonds suggested a 
possible involvement of arterial stiffening with endothelial dysfunction.(64) 
 
 On the other hand, intimal calcification was observed exclusively in 
atherosclerotic plaques, and was found to be due to imbalance between two 
opposing pathophysiological processes – inhibition of osteoclast – like cell 
mineral resorption and stimulation of osteoblast – like cell mineral deposition. 
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Three different models of plaque calcification proposed by Doherty and 
colleagues are explained below.(65) 
 
The “active model” of arterial calcification: 
Bostrom et al. showed the presence of pleuripotent arterial cells (calcifying 
vascular cells), that are immunologically distinct from the other arterial cells, co-
localised with bone-related proteins and transcriptional factors in the 
atherosclerotic plaques were found capable of forming mineralised structures.(66) 
 
The “passive physico-chemical model” of calcification: 
 This is based on the concept that calcium and phosphate ions are in a 
metastable state near the point of precipitation in solid phase within biological 
fluids and several proteins inhibited mineral salt deposition in the arteries as they 
contain glutamine residues carboxylated at the γ- position. Such proteins are 
called Gla proteins. According to this model, plaque calcification is due to 
defective γ- carboxylation of Gla proteins. The enzyme γ- carboxylase was found 
less active in the atherosclerotic vessels than in the normal vessels which may be 
due to the deficiency of the two co-factors (two isoforms of vitamin K- 
phylloquinone and menaquinone), needed for the chemical reaction.(67) Current 
evidence suggests that the passive model is associated with the medial 
calcification mainly a histological entity unrelated to atherosclerosis.(65) 
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The “arterial OCL model”: 
  While the active model highlights the importance of osteoblastic cells, the 
arterial OCL model advocates that the arterial calcification is due to the lack of 
activity of osteoclastic cells. Several factors influence its survival, maturation and 
function.  Macrophage – colony stimulating factor (M-CSF), a cytokine and a 
growth factor for mononuclear phagocytic cells is crucial in the survival and 
differentiation of osteoclastic progenitors. Lack of these factors can cause a 
reduction in the number of osteoclasts and development of calcification. 
 
On the other hand, the binding of RANKL to its receptor RANK initiates 
several intracellular signal transduction pathways and it appears to be an anti-
calcifying agent thereby reducing the plaque vulnerability. However Sandberg and 
his colleagues surprisingly showed that RANKL induces plaques instability in 
humans by inducing mononuclear phagocytic cells (MCP) and matrix 
metalloproteinases. Thus its exact role is unclear. Even though the full mechanism 
is unclear, OCL model is considered as directly involved in the intimal plaque 
calcification. 
 
The real difficulty is to define a specific marker for cardiovascular risk of 
plaque rupture not influenced by osteoporosis, renal failure and bone related 
disorders. Several studies indicate that the OPG/RANKL/RANK axis have been 
proposed as biomarkers of vascular risk and prognosis, although it is not specific 
for plaque calcification and destabilization. The serum levels of OPG were 
measured in patients with cerebrovascular disease, stable angina and coronary 
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artery disease, and showed interesting correlations. OPG levels were raised in 
patients with significant coronary narrowing. OPG gene polymorphisms were 
shown in coronary artery disease.(6,68,69) For this reason, the identification of 
isoforms of OPG could contribute for future diagnostic and prognostic 
significance.(65,70) 
 
Polymorphism of OPG gene:  
 Different single nucleotide polymorphisms have been found to be 
associated with osteoporosis – T245G, T950C and G1181C and they were 
evaluated in diabetes mellitus type 2 to study if they contributed to cardiovascular 
disease. The T950C is involved in normal vascular morphology and functions in 
healthy individuals. The homozygous polymorphism C-allele of T950C (950CC) 
was independently associated with an increased cardiovascular risk in type 2 
diabetes patients with elevated OPG levels.(49,69) 
 
OPG and cardiovascular events:   
 A strong positive correlation between OPG and cardiovascular risk was 
established.(71) OPG levels were found to be raised in patients with ST elevated 
myocardial infarction.(72,73) OPG levels correlated with cardiovascular risk factors 
like diabetes and metabolic syndrome.(74,75) Rasmussen et al. showed that the 
levels harmonized with basal glycaemia, glycosylated haemoglobin, blood 
pressure and endothelial dysfunction. Hence OPG can be used as an indicator for 
control of diabetes, endothelial dysfunction and cardiovascular risk. 
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OPG and subclinical atherosclerosis:  
 There is an increasing corroboration to show that endothelial dysfunction 
and increased coronary intimal medial thickness (CIMT) are forerunners of 
clinically detectable atherosclerosis. Diabetes is an entrenched risk factor for early 
development of accelerated atherosclerosis. However subclinical vascular 
involvement, in the form of endothelial dysfunction and increased CIMT, has 
been demonstrated in diabetes patients. Recently diagnosed diabetes patients      
(< 2 years) also demonstrated increased OPG levels. Olesen et al. observed 
significantly high levels of OPG in diabetic than non-diabetics. Ishiyama et al. 
showed that CIMT positively correlated with OPG levels.(76,77) 
 
 Increased OPG levels in diabetes were due to endothelial dysfunction 
which activates intracellular signalling pathways like eNOS (endothelial nitric 
oxide synthase) that impairs nitric oxide release from endothelial cells. Hence the 
nitric oxide levels are low and increased release of reactive oxygen species. (3,78) 
 
 Endothelial damage leads to the release of OPG from endothelial cells and 
smooth muscle cells. This is supposed to bring about anti-apoptotic effects by 
binding to TRAIL but instead it interferes with this cascade and acts as a response 
mechanism to counter the raised expression of TRAIL. Thus increased expression 
of OPG is a response to injury with resultant unintended cascade of events, while 
there is an ongoing process of inflammation. There is an increased amount of pro-
inflammatory cytokines and fibrosis due to SMC proliferation. This worsens 
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microvascular events which have to be explored in future. All these changes occur 
early in diabetes.  
 
OPG expression in endothelial cells in vitro: 
 Vascular endothelial cells (HUVECs) cultured in vitro released OPG. 
HUVECs were exposed to increased glucose concentration, insulin and 
inflammatory cytokines like TNF-α, the processes which occur in the sera of 
diabetic patients. Neither glucose nor insulin amounted to increase in levels of 
OPG even after 72 hours, suggesting that inflammatory cytokines increased OPG 
rather than hyperglycaemia as such.(79) Hence, diabetic vasculopathy has 
underlying inflammatory component manifesting itself in up-regulation of genes 
responsive to inflammatory process i.e. OPG is an NF-κB inducible gene whose 
release is increased by pro-inflammatory cytokines like TNF-α which are up-
regulated in the sera of diabetic patients.(80–82) Hyperinsulinism and insulin 
resistance do not modulate OPG release. (83,84) 
 
 Some studies suggest that increased OPG levels in cardiovascular disease 
may be due to a response to initial vascular insult and ongoing process of 
inflammation within an atherosclerotic plaque.(85,86) On the other hand, various 
studies highlight the pro-atherogenic role of OPG which itself takes part in 
different processes like endothelial cell dysfunction, macrophage activation, 
leukocyte adhesion and smooth muscle cell proliferation.(87–89) 
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OPG has a dichotomous role, both pro-atherogenic and anti-atherogenic 
effects held in a fine balance in normal individuals. But in face of persistent 
positive induction by various risk factors, the pro-atherogenic pathways become 
predominant. Although the prognostic utility of OPG seems a while away yet, it 
holds a great deal of promise in the accurate risk stratification of cardiovascular 
diseases and to assess the most adequate treatment.(3,49,90) 
  
Aims of the study 
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AIM OF THE STUDY 
 
1. To assess the level of plasma Osteoprotegerin in type 2 diabetes, diabetic 
patients with MI and healthy controls. 
 
2. To establish the role of  plasma Osteoprotegerin as a predictor of 
Myocardial Infarction in type 2 diabetes mellitus patients 
  
Materials and Methods 
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MATERIALS AND METHODOLOGY 
 
In the present study hundred subjects were chosen. Out of them, thirty were 
healthy, which included the staff of Madras Medical College – Central 
Biochemistry lab, their relatives and friends who formed the normal control of age 
group 35 to 75 years. Thirty of them were Type 2 Diabetes patients of age group 
35 to 75 years who visited the Diabetology OP of Rajiv Gandhi Govt. General 
Hospital. Another thirty were patients with Acute Myocardial Infarction and Type 
2 Diabetes of age group 35 to 75 years, admitted in the Intensive Coronary Unit of 
the Cardiology Department of Rajiv Gandhi Govt. General Hospital. This study 
was carried out between March 2017 and March 2018. 
 
INCLUSION CRITERIA: 
Patients with Type 2 Diabetes (newly detected) were selected based on the  
 
1. Symptoms of diabetes plus random blood glucose concentration ≥ 200 
mg/dL or 
2. Fasting plasma glucose ≥  126 mg/dL 
3. HbA1c ≥  6.5% 
4. Two hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance 
test. 
  
40 
 
 
WHO CRITERIA FOR ACUTE MI:  
Patients with acute Myocardial infarction were selected based on  
1. A history of characteristic prolonged chest pain. 
2. Electrocardiogram showing the new Q waves or new abnormal ST – T 
features. 
3. Elevated levels of known cardiac biomarkers – CK, CK – MB. 
 
EXCLUSION CRITERIA: 
1. Type 1 diabetes mellitus patients. 
2. Hypertension (resting systolic blood pressure > 140 mmHg and diastolic 
blood pressure > 90 mmHg) 
3. Presence of concomitant systemic diseases (chronic liver disease, renal 
disorder, cancer, sepsis and auto immune diseases). 
4. Bone related diseases 
5.  Critically ill patients 
6. Ongoing or recent infectious diseases 
7. Surgical procedures in preceding 3 months. 
 
BLOOD COLLECTION: 
 Blood samples were collected by venipuncture. About 2 mL of blood was 
collected in K2 EDTA tube, plasma were separated from the tubes after 
centrifugation at 3000 g for 10 minutes in a refrigerated centrifuge. Blood from 
myocardial infarction patients were collected within 6 – 12 hours after the onset 
of chest pain.  The levels of glucose, total cholesterol, triglycerides, HDL, total 
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creatine kinase, creatine kinase – MB, lactate dehydrogenase and aspartate 
transaminase (AST) were measured immediately. About 0.5 mL of plasma was 
stored in an eppendorf at – 20°C for the Osteoprotegerin assay. 
 
METHODOLOGIES FOR VARIOUS ANALYTES 
ESTIMATION OF PLASMA OSTEOPROTEGERIN 
 
Enzyme linked immunosorbent assay (ELISA) 
Principle:  
 Osteoprotegerin (OPG) is added to the wells pre-coated with OPG 
monoclonal antibody. After incubation, a biotin-conjugated anti human OPG 
antibody is added and binds o human OPG. After incubation unbound biotin-
conjugated anti human OPG antibody is washed away during a washing step. 
Streptavidin-HRP is added and binds to the biotin-conjugated anti human OPG. 
Substrate solution is then added and colour develops in proportion to the amount 
of OPG. The reaction is terminated by the addition of acidic stop solution and 
absorbance is measured at 450 nm. 
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Reagents provided: 
S. 
NO REAGENTS QUANTITY 
1. STANDARD (16 ng/mL) 0.5 mL 
2. PRE-COATED ELISA PLATE 12*8 WELL STRIPS 
3. STANDARD DILUENT 3 mL 
4. STREPTAVIDIN-HRP 6 mL 
5. SUBSTRATE SOLUTION A 6 mL 
6. SUBSTRATE SOLUTION B 6 mL 
7. STOP SOLUTION 6mL 
8. WASH BUFFER CONCENTRATE (30X) 20 mL 
9. BIOTIN-CONJUGATE ANTI-HUMAN OPG ANTIBODY 1mL 
 
Precautions taken before using the reagents: 
1. Prior to the procedure, the reagents and samples were brought to room 
temperature naturally in 30 minutes. 
2. The reagents were covered when not in use. 
3. The pipetting order and the rate of addition from well-to-well were made 
sure. 
4. Substrate solution B is light sensitive and was protected from light. 
5. Stop solution contained acid and was used cautiously. 
6. Pipette tips and plate sealers were clean and disposed properly. 
  
43 
 
Reagent preparation: 
1. Standard preparation: Dilution of standard solutions suggested are as 
follows: 
8ng/ml Standard No.5 120μL Original Standard + 120μL Standard diluent 
4ng/ml Standard No.4 120μL Standard No.5  +  120μL Standard diluent 
2ng/ml Standard No.3 120μL Standard No.4  +  120μL Standard diluent 
1ng/ml Standard No.2 120μL Standard No.3  +  120μL Standard diluent 
0.5ng/ml Standard No.1 120μL Standard No.2  +  120μL Standard diluent 
 
Fig.1 Standard preparation 
 
 
 
Standard S5 S4 S3 S2 S1 
16ng/ml 8ng/ml 4ng/ml 2ng/ml 1ng/ml 0.5ng/ml 
 
  
16ng/mL 
Original 
Standard 
120 μL 120 μL 120 μL 120 μL 120 μL 
8ng/mL 4ng/mL 2ng/mL 1ng/mL 0.5ng/mL 
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2. Wash buffer concentrate (30x) was diluted with distilled water. 
3. Washing method: the solution in the plate was discarded without touching 
the sides and the plate was blotted on to absorbent paper. 
 
Procedure:  
Reagents were brought to room temperature before use. Standard solutions were 
prepared and the assay was performed at room temperature. 
 
1. 50 μL standard was added to the standard well. 
2. 40 μL of sample was added to the sample wells and 10 μL anti OPGL 
antibody was added to the sample wells. Then 50 μL of streptavidin-HRP 
was added to the sample and standard wells. The plate was mixed well. It 
was covered with a sealer and incubated at 37 °C for 60 minutes. 
3. The sealer was removed from the plate and it was washed 5 times with 
wash buffer using ELISA plate washer. The plate was blotted on to paper 
towels. 
4. 50 μL of substrate solution A was added to each well and 50 μL of 
substrate solution B was added to each well. The plate was covered with a 
new sealer and incubated for 10 minutes at 37 °C in the dark. 
5. 50 μL of stop solution was added to each well and the blue colour changed 
to yellow immediately.  
6. The optical density (OD) of each well was determined using a micro-plate 
reader set to 450 nm within 30 minutes of adding stop solution. 
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Fig. 2: Procedure of Enzyme Linked Immnunosorbent Assay (ELISA) for 
osteoprotegerin 
  
Prepare the reagents and standards as per 
instructions
Add 50 μL of standard to each standard well 
Add 40 μL of sample and 10 μL of anti-OPG Ab to 
sample wells
Add 50 μL of Streptavidin-HRP to both standard 
and sample wells
Incubate at 37°C for 60 minutes
Aspirate and wash for 5 times
Add 50 μL of substrate A and 50 μL of substrate B  
to each well
Incubate at 37°C for 10 minutes
Add 50 μL of stop solution to each well
Read at 450 nm within 30 minutes
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Calculation of results: 
 A standard curve was constructed by plotting the average optical density 
(OD) for each standard on vertical axis (Y) and concentration of osteoprotegerin 
(OPG) on the horizontal axis (X). A best fit curve was drawn through the points 
on the graph by regression analysis. 
 
Fig.3 The Standard curve for Osteoprotegerin 
 
 
Concentration and optical densities of the standards 
STANDARD CONCENTRATION (ng/mL) OPTICAL DENSITY 
S5 8 1.8 
S4 4 1.002 
S3 2 0.679 
S2 1 0.475 
S1 0.5 0.263 
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ESTIMATION OF CREATINE KINASE – NAC REAGENT - UV KINETIC 
METHOD  
 
Principle:   
 The enzyme creatine kinase, catalyses the first reaction; Glucose is 
phosphorylated by hexokinase in the next reaction. D-glucose-6-phosphate is 
oxidised by glucose 6-phosphate dehydrogenase which uses the coenzyme NAD. 
The rate of formation of NADH is measured at 340 nm and it is directly 
proportional to the serum creatine kinase activity. 
 
 N-acetyl cysteine is included to activate creatine kinase and EDTA to bind 
calcium and to increase the stability of reaction mixture. 
 
       Creatine kinase 
1. Creatine phosphate   +   ADP                                     Creatine    +    ATP 
 
          Hexokinase 
2. ATP   +    D-Glucose    ADP   +   Glucose-6-phospate    
 
      G-6 PDH 
3. Glucose-6-phosphate   +   NAD+                                                             6-phosphogluconate + 
         NADH + H+ 
 
Reagents: 
Imidazole buffer (pH 6.1)                - 125 mmol/L       
Glucose                                              - 25 mmol/L 
Magnesium acetate                           - 12.5 mmol/L 
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EDTA                                                 - 2 mmol/L 
N-acetyl cysteine                                - 25 mmol/L 
NADP                                                  - 2.4 mmol/L 
Hexokinase                                          - > 6.8 U/L 
ADP                                                     - 15.2 mmol/L 
G-6-PD                                                  - > 8.8 U/mL 
Creatine phosphate                                 - 250 mmol/L 
AMP                                                       - 25 mmol/L 
Diadinosine pentaphosphate            - 103 μmol/L 
 
Sample: Plasma 
 
Procedure: 25 μL of sample is added to 1000 μL of reagent and the mixture is 
incubated at 37 °C for 1 minute and the absorbance is measured at 340 nm. 
 
Calculation:  
U/L  = ΔAbs/minute  x 6592 
 
     1000    Volume in the cuvette 
U/L  = ΔAbs/minute       x        -------------     x     ---------------------------- 
            Volume of        Molar absorbance 
            Serum used             of the nucleotide 
 
 
Reference range:     Males – 46 – 171 U/L, Females – 34 – 145 U/L(42) 
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ESTIMATION OF CREATINE KINASE – MB (UV KINETIC METHOD) 
 
Principle:  
 Creatine kinase –MB is composed of creatine kinase-M and B. Creatine 
kinase-M moiety alone will be inhibited by a specific antibody and it will not 
affect the creatine kinase-B moiety. The creatine kinase-B fraction accounts for 
one half of the activity of creatine kinase-M, which is determined. 
 
Reagents: 
R1 Imidazole buffer (pH 6.1)        - 125 mmol/L  
 Glucose     - 25 mmol/L 
Magnesium acetate                           - 12.5 mmol/L 
EDTA                                                 - 2 mmol/L 
N-acetyl cysteine                                - 25 mmol/L 
NADP                                                  - 2.4 mmol/L 
Hexokinase                                          - > 6.8 U/L 
Anti CK Ab                                             - 2000 U/L 
 
R2     ADP                                                     - 15.2 mmol/L 
 G-6-PD                                                  - > 8.8 U/mL 
 Creatine phosphate                                 - 250 mmol/L 
 AMP                                                       - 25 mmol/L 
 Diadinosine pentaphosphate            - 103 μmol/L 
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Sample: Plasma 
 
Procedure: 50 μL of sample is added to 1000 μL reagent and is incubated at 37°C 
for 1 minute and reading is taken at 340 nm. 
 
Calculation:  
U/L  = ΔAbs/minute  x 3376 
 
     1000     Volume in the cuvette 
U/L  = ΔAbs/minute       x        -------------   x      ---------------------------- 
            Volume of        Molar absorbance 
            serum used             of the nucleotide 
 
Reference range: 0 – 25 U/L(42)  
 
ESTIMATION OF LACTATE DEHYDROGENASE (UV KINETIC 
METHOD) 
Principle:  
 Pyruvate is reduced to lactate by the enzyme lactate dehydrogenase (LDH) 
with the help of coenzyme NADH. The NAD formed is directly proportional to 
the reduction of pyruvate in equimolar form and the decrease in absorbance at   
340 nm depicts the LDH activity in the sample. 
     LDH 
Pyruvate       +      NADH                                 Lactate     +     NAD + H+ 
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Reagent:  
R1  Tris buffer (pH 7.5) – 100 mmol/L 
 Pyruvate  - 2 mmol/L 
R2   NADH – 1.66 mmol/L 
 
 In order to prepare the monoreagent, mix four portions of R1 and one 
portion of R2. 
 
Sample: Plasma 
 
Procedure: 1000 μL of reagent is mixed with 20 μL of sample and the mixture is 
incubated at 37 °C for 1 minute. The reading is observed at 340 nm. 
 
Calculation:  
U/L  = ΔAbs/minute  x 8200 
 
     1000   Volume in the cuvette 
U/L  = ΔAbs/minute       x        -------------   x   ---------------------------- 
            Volume of        Molar absorbance 
             serum used             of the nucleotide 
 
 
Reference range:180 – 360 U/L (42) 
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ESTIMATION OF ASPARTATE AMINO TRANSFERASE (MODIFIED 
IFCC METHOD) 
 
Principle:  
 An amino group is transferred to alpha ketoglutarate by aspartate 
aminotransferase (AST) to form glutamate and oxaloacetate.Oxaloacetate is 
reduced to malate by malate dehydrogenase (MDH) which uses NADH. This 
resulting decrease in absorbance at 340 nm is followed spectrophotometrically 
corresponds to the AST activity.  
 
      AST 
L-Aspartate  +  Alpha ketoglutarate                        Oxaloacetate  +  L-glutamate 
 
      MDH 
Oxaloaxcetate   +   NADH+H+                                                                 L- malate + NAD+ 
 
Reagent: AST reagentis prepared by mixing four parts of R1 and one part of R2. 
 
R1  Tris buffer (7.8 pH)  - 88 mmol/L 
 L-Aspartate   - 260 mmol/L 
 LDH     - > 1500 U/L 
 MDH    - > 900 U/L 
 
R2  Alpha ketoglutarate  - 12 mmol/L 
 NADH   -  0.24 mmol/L 
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Sample: Plasma 
 
Procedure: The reagent is first prepared by mixing four parts of R1 and one part 
of R2. A mixture of reagent (1000 μL) and sample (100 μL) is incubated at 37°C 
for 1 minute and the decreasing absorbance is recorded at 340 nm. 
 
Calculation:  
U/L  = ΔAbs/minute  x 1745 
 
     1000   Volume in the cuvette 
U/L  = ΔAbs/minute       x        -------------   x   ---------------------------- 
            Volume of        Molar absorbance 
            serum used             of the nucleotide 
 
Reference range:  Males - < 35 U/L, Females - < 31 U/L (42) 
 
ESTIMATION OF GLUCOSE (HEXOKINASE METHOD) 
 
Principle: 
 Hexokinase phosphorylates glucose to glucose-6-phosphate by ATP. 
Glucose-6-phosphate dehydrogenase oxidizes glucose-6-phosphate in the 
presence of NADP to gluconate-6-phosphate. The rate of NADPH formation 
during the reaction is directly proportional to the glucose concentration and is 
measured photometrically. 
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Hexokinase 
Glucose    +   ATP                                                Glucose-6-phosphate    +     ADP 
 
 
           G-6-PDH 
Glucose-6-phosphate  +  NADP+                                                   Gluconate-6-phosphate +  
              NADPH + H+ 
Reagent:  
R1  Trisbuffer (pH 7.8)   - 100 mmol/L 
Mg2+    - 4 mmol/L 
ATP      - 2.1 mmol/L 
NAD     - 2.1 mmol/L 
R2 Mg2+    - (4 mmol/L) 
           Hexokinase     - ≥ 7.5 kU/L 
 G-6-PDH   - ≥ 7.5 kU/L 
 
The reagent is prepared by mixing four volumes of R1 and one volume of R2. 
 
Sample:  Plasma sample 
 
Procedure: 
 Reagent: 1000 μL 
 Sample:   10 μL 
 At 25 °C, the mixture is incubated for 10 minutes and the absorbance is 
read against reagent blank at 340 nm. 
 
Reference range: 
 Random blood glucose - <140 mg/dL 
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ESTIMATION OF PLASMA TOTAL CHOLESTEROL 
(CHOLESTEROL ESTERASE – CHOLESTEROL OXIDASE METHOD) 
 
Principle:  
    Cholesterol esterase 
Cholesterol ester + H20                                            Cholesterol  +  Fatty acids 
 
    Cholesterol exidase 
Cholesterol  + O2                                                                                         Cholestenone + H2O2 
 
              Cholesterol esterase 
H2O2   +    Phenol  +  4-Aminoantipyrine                              quinone dye  +  4H2O 
 
 
 The concentration of cholesterol in the sample is equivalent to the intensity 
of the red complex (red quinone), which is measured at 505 nm. 
 
Reagents:  
R1 Good’s buffer   - 50  mmol/L 
 Phenol    - 5 mmol/L 
4-aminoantipyrine  - 0.3 mmol/L 
Cholesterol esterase  - 200U/L 
Cholesterol oxidase  - 50 U/L 
Peroxidise   - >3 k U/L 
R2 Sodium cholate 
 
Sample:  Plasma sample 
  
56 
 
Procedure:  
 1 mL of reagent is combined with10 μL of sample and incubated for 5 min 
at 37°C and the absorbance of the sample is measured against the reagent blank at 
505 nm. 
 
Reference range:  Normal - < 200 mg/dL 
             Borderline high – 220 – 239 mg/dL 
                               High - > 239 mg/dL(42) 
 
ESTIMATION OF PLASMA TRIGLYCERIDE 
(ENZYMATIC – GLYCEROL-3-PHOSPHATE METHOD) 
 
Principle: 
           Lipoprotein lipase 
Triglycerides   +   H2O                                 Glycerol + Fatty acid 
 
   Glycerol kinase 
Glycerol   +  ATP     Glycerol-3-phosphate  +  ADP 
 
      G-3-P oxidase 
Glycerol-3-phosphate                            Dihyhdroxy acetone phosphate  + H2O2 
 
          Peroxidase 
2H2O2 + 4-Aminopyrine + ADPS                                  Red quinine + H2O 
 
 
Reagents:  
R1 Lipoprotein lipase (4000 U/L), 
 Glycerol kinase (1500 U/L), 
 Glycerol 3 – phosphate oxidase (4000 U/L), 
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ATP (2.0 mmol/L), 
Pipes buffer - pH 7.0 (40 mmol/L), 
Mg2+(2.5 mmol/L) 
ADPS (0.2 mmol/L) 
 
R2      4-aminoantipyrine (0.4 mmol/L) and peroxidase (2200 U/L). 
 
The reagent is reconstituted by mixing four volumes of R1 and one volume of R2. 
 
Standard: Glycerol (Triglyceride equivalent) – 200 mg/dL 
 
Sample:  Plasma sample 
 
Procedure: To   1 mL of the reconstituted reagent 10 μL of plasma is added and 
read at 546 nm after incubation at 37°C for 5 minutes. 
 
Reference range:   Normal - < 150 mg/dL 
   High – 150 – 199 mg/dL 
   Hypertriglycerdemic – 200 – 499 mg/dL 
   Very high - > 499 mg/dL(42) 
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ESTIMATION OF HDL CHOLESTEROL - IMMUNOINHIBITION 
Principle  
 Chylomicrons, VLDL, and LDL fractions in plasma are separated from 
HDL by immunoinhibition. Anti human β-lipoprotein antibody in reagent 1 binds 
to lipoproteins (chylomicrons, VLDL and LDL) other than HDL antigen – 
antibody complexes formed block enzyme reactions when reagent 2 is added. 
Cholesterol esterase (CHE) and cholesterol oxidase (CO) in reagent 2 react only 
with HDL-C. Hydrogen peroxide produced by enzyme reactions with HDL-C, 
yields a blue coloured complex upon oxidase condensation with F-DAOS and 4-
aminoantipyrine (4-AAP) in the presence of peroxidise. The intensity of the blue 
coloured complex formed at 593 nm is proportional to HDL-C in the sample. 
 
 
    Anti – Lipoprotein B antibody 
LDL, VLDL, Chylomicrons                   Antigen–antibody complex 
 
        CHE & CO 
HDL-C + H2O + O2                         4-Cholestenone + Fatty acid + H2O2 
 
    Peroxidase 
H2O2 + DAOS + 4 AAP                                 Blue coloured complex + 2H2O 
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REAGENTS 
Reagent 1 
Goods buffer (pH  7.0)- 30 mmol/L 
4- Amino antipyrine- 0.9 mmol/L 
Peroxidise- 2400 U/L 
Ascorbate oxidase- 2700 U/L 
Anti human β-lipoprotein antibody 
 
Reagent 2 
Goods buffer (pH 7.0) - 30 mmol/L 
Cholesterol esterase- 4000 U/L 
Cholesterol oxidase - 20,000 U/L 
F-DAOS - 0.8 mmol/L 
 
Sample:  Plasma sample 
 
Standard:  HDL –C   56.5 mg/dL 
 
Procedure:          
 Reagent 1 & 2 are mixed in the ratio of 3:1 and placed in the auto analyser 
along with the following assay parameters: 
 
Assay type        : 2 point 
Primary wavelength   : 600 nm 
Secondary wavelength  : 700 nm 
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R-1 volume    : 270 μL 
R-2 volume    : 90 μL 
Sample volume   : 3 μL 
 
Reference Range: Males:  35.3 – 79.5 mg/dL 
   Females:    42.0 – 88.0 mg/dL 
 
VLDL & LDL CHOLESTEROL 
These parameters were calculated using Friedwald’s formula given below: 
LDL-C      =            T. CHOLESTEROL   –   (HDL-C   +   VLDL-C) 
VLDL-C   =             TGL/5 
  
Results 
  
S. NO AGE SEX
OSTEO 
PROTEGERIN 
(ng/mL)
P. GLUCOSE 
(mg/dL)
T. CHOL 
(mg/dL)
TGL 
(mg/dL)
HDL 
(mg/dL)
LDL 
(mg/dL)
CK 
(U)
CK MB 
(U)
LDH 
(U)
SGOT 
(U)
ECG
1 35 M 12.19 102 138 97 26 71.6 105 20 207 56 NSR
2 54 M 7.01 74 138 110 30 90.2 61 12 207 14 NSR
3 40 F 7.3 80 132 130 78 11 70 21 212 28 NSR
4 45 F 7.2 80 119 78 32 64.6 64 10 114 21 NSR
5 38 M 6.99 68 83 103 34 35.8 109 22 161 25 NSR
6 60 F 10.49 141 130 49 32 80.2 85 18 121 14 NSR
7 35 F 9.19 121 159 53 30 102.6 96 11 140 10 NSR
8 38 F 7.28 79 97 102 46 59 80 13 126 40 NSR
9 60 F 6.5 72 102 103 25 61.2 47 10 172 10 NSR
10 54 F 7.32 76 107 115 25 72.6 39 13 170 40 NSR
11 38 F 8.8 70 124 68 32 70.6 88 16 167 17 NSR
12 40 F 7.32 82 135 126 40 85.6 123 13 172 16 NSR
13 55 M 8.72 90 97 75 33 64.2 31 19 110 25 NSR
14 35 M 9.48 77 113 120 34 66.6 65 16 153 31 NSR
15 45 F 7.09 75 241 89 50 172.4 48 12 201 35 NSR
16 50 F 8.68 104 102 92 33 66.8 79 13 183 52 NSR
17 60 M 9.08 111 102 100 32 67.8 72 12 189 12 NSR
18 38 F 9.06 111 111 102 38 43.4 68 10 166 32 NSR
19 38 F 7 76 119 110 34 77.2 74 17 119 16 NSR
20 37 M 8.15 81 122 126 36 71.4 79 16 181 36 NSR
21 42 F 9.03 96 124 187 35 71.8 76 11 178 30 NSR
22 60 M 10.34 102 87 159 32 58.2 72 14 171 42 NSR
23 35 F 10.86 129 92 49 38 61 44 10 188 17 NSR
24 55 F 11.04 135 139 74 42 60.2 66 11 167 12 NSR
25 55 F 11.71 158 170 43 47 87.6 62 13 130 26 NSR
26 58 M 19.17 279 77 118 36 47 90 11 145 33 NSR
27 36 F 9.38 110 112 115 33 68 108 10 135 32 NSR
28 42 F 8.74 98 147 74 40 34 55 12 170 15 NSR
29 62 M 10.11 108 136 43 47 87.8 69 15 132 28 NSR
30 43 F 6.92 92 128 80 35 84.2 72 17 110 20 NSR
MASTER CHART  -  CONTROLS
S. NO AGE SEX
OSTEO 
PROTEGERIN 
(ng/mL)
P. GLUCOSE 
(mg/dL)
T. CHOL 
(mg/dL)
TGL 
(mg/dL)
HDL 
(mg/dL)
LDL 
(mg/dL)
CK 
(U)
CK MB 
(U)
LDH 
(U)
SGOT 
(U)
ECG
1 52 F 9.34 166 167 172 32 121.6 74 11 160 12 NSR
2 65 F 18.2 247 166 64 35 114 48 10 172 10 NSR
3 55 F 22.14 268 383 526 35 279 70 10 157 35 NSR
4 60 F 16.73 208 169 122 30 121.4 58 13 187 11 NSR
5 55 M 40 292 138 36 40 83.4 81 14 190 19 NSR
6 65 M 5.31 211 134 69 36 92.2 67 22 210 11 NSR
7 54 M 45 352 98 117 33 57.4 72 14 172 10 NSR
8 42 M 14.55 180 175 55 27 108.6 62 20 141 14 NSR
9 47 F 16.05 203 130 64 28 84.4 60 13 157 16 NSR
10 35 F 22.18 184 84 52 24 36 103 23 243 56 NSR
11 45 M 14.28 165 171 62 41 125.4 104 23 161 26 NSR
12 54 M 13.64 225 169 87 32 103.8 130 21 167 13 NSR
13 44 F 11.74 184 150 64 20 102 32 10 165 16 NSR
14 52 F 10.59 151 171 97 27 113 167 16 199 11 NSR
15 64 F 10.03 144 266 103 48 198.2 72 15 199 21 NSR
16 49 F 12.52 148 190 66 22 138.6 54 16 171 32 NSR
17 55 F 9.31 165 160 76 19 108 40 23 161 42 NSR
18 44 F 10.56 167 158 193 29 99.6 62 18 145 16 NSR
19 44 F 11.6 175 170 79 26 114 72 10 132 22 NSR
20 65 M 24.03 187 201 93 32 139.8 138 19 138 34 NSR
21 64 F 18.38 150 190 116 29 117.6 81 13 143 15 NSR
22 57 F 18.63 225 224 84 12 160.2 34 13 159 20 NSR
23 48 F 12.75 195 98 55 20 50.2 66 22 208 18 NSR
24 50 F 10.89 153 147 254 28 90.2 17 46 181 16 NSR
25 40 M 34.18 279 164 207 41 108.4 23 5 179 35 NSR
26 57 F 13.15 181 104 55 19 44.4 54 17 169 42 NSR
27 39 M 12.1 171 102 65 31 46 138 13 192 39 NSR
28 55 M 21.52 235 140 465 20 85.2 68 16 168 52 NSR
29 58 M 40.09 287 160 116 25 104.4 120 15 197 32 NSR
30 56 M 43 320 154 109 22 103 105 20 203 42 NSR
MASTER CHART  -  CASES : TYPE 2 DIABETES MELLITUS PATIENTS
S. NO AGE SEX
OSTEO 
PROTEGERIN 
(ng/mL)
P. GLUCOSE 
(mg/dL)
T. CHOL 
(mg/dL)
TGL 
(mg/dL)
HDL 
(mg/dL)
LDL 
(mg/dL)
CK 
(U)
CK MB 
(U)
LDH 
(U)
SGOT 
(U)
ECG
1 52 F 40.3 300 105 120 28 53 155 72 596 87 STEMI
2 71 F 45.11 371 112 105 24 67 395 71 292 91 STEMI
3 42 M 39.01 304 325 252 20 254.6 191 24 235 68 STEMI
4 47 M 45 376 156 99 18 118.2 406 34 300 36 STEMI
5 60 M 10.6 151 262 142 23 210.6 886 47 256 70 STEMI
6 43 M 43.1 325 141 162 19 89.6 2087 117 232 247 STEMI
7 52 F 46.01 416 128 92 20 89.6 2678 159 3119 221 STEMI
8 62 F 24.38 297 124 109 23 79.2 1444 108 575 162 STEMI
9 64 F 39.51 324 271 91 25 227.8 713 63 654 114 STEMI
10 50 M 17.71 281 231 198 20 171.4 276 22 381 54 STEMI
11 75 M 24.04 222 175 211 25 107.8 187 12 295 28 STEMI
12 61 M 12.2 160 225 169 23 168.2 246 33 243 37 STEMI
13 39 F 33.64 304 146 166 30 82.8 86 18 281 51 STEMI
14 60 M 13.76 173 218 273 26 137.4 222 34 216 32 STEMI
15 58 M 13.45 220 150 85 30 103 493 71 241 76 STEMI
16 63 F 15.39 281 188 566 25 49.8 315 43 185 34 STEMI
17 45 M 10.98 225 106 162 29 44.6 782 72 274 34 STEMI
18 50 F 47.02 487 236 126 31 179.8 537 54 377 69 STEMI
19 57 M 11.4 118 135 133 30 78.4 225 19 341 22 STEMI
20 65 M 14.04 185 113 75 24 74 534 85 401 186 STEMI
21 63 M 20.54 286 117 244 18 50.2 173 19 185 24 STEMI
22 62 M 12.35 169 140 90 30 92 395 47 299 22 STEMI
23 48 M 14.72 183 246 225 25 176 58 18 252 29 STEMI
24 70 M 21.44 291 111 71 25 71.8 366 67 475 94 STEMI
25 66 M 36.91 311 191 153 21 139.4 696 60 467 146 STEMI
26 50 M 35.65 305 175 137 31 116.6 2715 203 593 246 STEMI
27 45 M 14.17 209 118 208 23 53.4 347 31 375 54 STEMI
28 54 M 19.43 185 113 76 17 80.8 574 87 421 178 STEMI
29 52 M 14.43 155 150 105 19 110 488 49 432 97 STEMI
30 72 M 20.76 233 150 81 22 111.8 294 43 499 54 STEMI
MASTER CHART  -  CASES: TYPE 2 DIABETES MELLITUS  PATIENTS WITH MYOCARDIAL INFARCTION
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KEY TO MASTER CHART 
OPG                    - osteoprotegerin 
GLU                       - glucose 
T.CHOL                 - total cholesterol 
TGL                        - triglycerides 
HDL                        - high density lipoprotein 
LDL                        - low density lipoprotein 
CK                           - creatine kinase 
CK-MB                   - creatine kinase -MB 
LDH                        - lactate dehydrogenase 
AST                        - aspartate transaminase 
ECG                        - electrocardiogram 
MI                           - myocardial infarction 
  
Statistical Analysis 
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STATISTICAL ANALYSIS 
 
 The data were analysis using SPSS (Statistical Package for Social Science) 
Version 20.00. The data collected were scored and analyzed, continues variables 
were presented as means with standard deviation (SD) and categorical variables 
were presented as frequency and percentages. Student t-test was used to compare 
two means & Standard deviations and analysis of variance (ANOVA) was used to 
compare more than two means & Standard deviations. Chi-square test was used to 
compare proportions.  Correlations were used to find out the linear relationship of 
the variables. Receiver operating characteristics (ROC) curves were used to 
classify the performance of osteoprotegerin. All the statistical results were 
considered significant at    p-value ≤ 0.05. 
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RESULTS 
 
TABLE-1: OSTEOPROTEGERIN OF THE STUDY SUBJECTS 
 CONTROL (C) 
DIABETES 
MELLITUS 
(D) 
DIABETES 
with MI C vs D 
C Vs D 
with MI 
D Vs D 
with 
MI 
N 30 30 30 p-value 
Mean 9.07 18.75 25.24 
0.001** 0.001** 0.04* 
SD 2.46 10.89 12.98 
F-value 20.33 
p-value 0.001** 
Significant Highly Significant 
 
**- Highly significant; *- Significant 
 
Table 1 shows the comparison of osteoprotegerin levels between the 
controls and cases. Participants were classified into three groups: controls (n=30), 
type 2 diabetics (n=30) and diabetics with MI (n=30). There was a highly 
significant statistical difference between the control and cases as determined by 
ANOVA test (F=20.33, p= 0.001). The diabetics with MI had significant 
statistically higher values of OPG when compared to diabetics and control groups.  
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FIGURE 1: 
 
Figure 1 shows that the diabetics with MI had significant statistically higher 
values of OPG when compared to diabetics and control groups.  
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TABLE-2: GLUCOSE VALUES OF THE STUDY SUBJECTS 
 CONTROL (C) 
DIABETES 
MELLITUS 
(D) 
DIABETES 
with MI C vs D 
C Vs D 
with MI 
D Vs D 
with MI 
N 30 30 30 p-value 
Mean 102.57 207.27 261.57 
0.001** 0.001** 0.005** 
SD 40.83 55.17 86.62 
F-value 48.23 
p-value 0.001** 
Significant Highly Significant 
 
**- Highly significant; *- Significant 
Table 2 shows the comparison of glucose values between the cases and controls. 
The participants are categorized into three groups: group 1- controls (n=30), group 
2 - diabetics (n=30) and group 3 - diabetics with MI (n=30). Therewas a 
significant statistical difference between the controls and cases as determined by 
ANOVA (F = 48.23, p = 0.001). Group 3 with higher glucose values shows the 
increased risk of MI with poor glycaemic control. 
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FIGURE 2: 
 
Figure 2 shows that group 3 (diabetics with MI) had a significant statistically 
higher glucose values. 
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TABLE-3: CORRELATION BETWEEN OSTEROPROTEGERIN AND 
GLUCOSE 
 
 DIABETES MELLITUS DIABETES with MI 
r 0.87 0.88 
Significant 0.001** 0.001** 
 
**- Highly significant; *- Significant 
 
Table 3 shows the correlation between OPG and glucose in the Diabetics 
and diabetics with MI patients. From this table it is inferred that OPG and glucose 
have a statistically highly significant linear relationship (p < 0.001) in both the 
disease groups. The direction of the relationship is positive (i.e. they are positively 
correlated), elucidating that these variables tend to increase together (i.e. greater 
levels of glucose are associated with increased OPG levels). 
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FIGURE 3: 
 
 
FIGURE 4: 
 
Figure 4 & 5 show a positive correlation between glucose and osteoprotegerin. 
These variables tend to increase together in both diabetics and diabetics with MI.  
 
0
50
100
150
200
250
300
350
400
0 10 20 30 40 50
CORRELATION BETWEEN OSTEROPROTEGERIN 
AND  GLUCOSE IN DIABETES MELLITUS
0
100
200
300
400
500
600
0 10 20 30 40 50 60
CORRELATION BETWEEN OSTEROPROTEGERIN AND  
GLUCOSE IN DIABETICS WITH MYOCARDIAL 
INFARCTION
69 
 
 
FIGURE 5: 
OSTEOPROTEGERIN (CONTROL & DIABETES)
 
 
 Fig.5 ROC curve for the diagnosis of diabetes. The area under the ROC 
curve for the diagnosis of diabetes was 0.900 with a sensitivity of 91.5% and 
specificity of 94.3%, PPV = 95.5% and NPV = 85.5%; SE = 0.043 and a 
confidence interval from 0.815 to 0.985. 
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AREA UNDER THE CURVE 
Test Result Variable(s): OSTEOPROTEGERIN 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.900 .043 .000 .815 .985 
 
a. Under the nonparametric assumption 
b. Null hypothesis: true area =0.5 
 
BASED ON ROC 
VARIABLE  
Area Under Curve (AUC) 0.90 
Optimal cut off value 11.00 
Sensitivity 91.51% 
Specificity 94.39% 
Positive Predictive Value 95.53% 
Negative Predictive Value 85.55% 
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FIGURE 6: 
OSTEOPROTEGERIN (CONTROL & DIABETES WITH MI) 
 
 
 
 Fig.6 ROC curve for the diagnosis of MI. The area under the ROC curve is 
0.976 for the diagnosis of MI with a sensitivity of 93% and specificity of 97.5%, 
PPV= 98.5% & NPV = 89.5%; SE = 0.017 and confidence interval from 0.942 to 
1.009. 
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AREA UNDER THE CURVE 
Test Result Variable(s): OSTEOPROTEGERIN 
Area Std. Errora Asymptotic Sig.b 
Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.976 .017 .000 .942 1.009 
 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
BASED ON ROC 
VARIABLE  
Area Under Curve (AUC) 0.98 
Optimal cut off value 12.00 
Sensitivity 93.41% 
Specificity 97.59% 
Positive Predictive Value 98.57% 
Negative Predictive Value 89.59% 
 
 
 
 
 
 
 
Discussion 
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DISCUSSION 
 
 Coronary artery disease (CAD) is considered as a modern epidemic by 
WHO. It is charged with 25-30% of all deaths and the natural history is variable.  
 
 The risk of CAD is higher in diabetics than non – diabetics. It is 
responsible for 30 – 50 % of deaths in diabetics over 40 years of age in the 
developed countries. In many developed countries, there is a downturn in the 
mortality due to CAD associated with causes other than diabetes. But the upsurge 
of coronary risk factors associated with diabetes increases risks thereby the 
mortality rate remains unchanged.(91) 
 
 Endothelial damage ushers to the release of OPG from endothelial cells 
and smooth muscle cells which is a response to injury with concomitant cascade 
of events during an ongoing inflammation. These changes occur earlier in 
diabetes.(83) 
 
 In our study, in patients with diabetes, subclinical vascular involvement in 
the form of endothelial dysfunction and increased coronary artery intimal 
thickness (CIMT) leads to raised OPG levels. This is in concordance with Olesen 
et al. and Ishiyama et al. Both observed significantly high levels of OPG in 
diabetic than non-diabetics and CIMT positively correlated with OPG levels.(92,93) 
 
 The mean level of OPG in normal healthy individuals was 9.07 ng/mL and 
a standard deviation of ± 2.47ng/mL, according to this present study.  
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 In diabetics, significant increase in the OPG levels was noticed with a 
mean of 18.75 ng/mL and a standard deviation of ± 10.8ng/mL which correlates 
with the study by Olesan et al., Rasmussen et al. and Altinova et al.(92,94,95) 
 
 In diabetics with MI, highest levels of OPG were perceived, with a mean 
of 25.24 ± 12.9 ng/mL which is congruous with the study by Browner et al., 
Avignon et al., Rasmussen et al., Blazquez-Medela et al. and Poulsen et al.(94,96–99) 
 
In this present study, no significant association between OPG, age and 
gender were observed. Irrespective of age of onset of diabetes, subclinical 
endothelial dysfunction and intimal thickness occurs, hence there is no association 
between OPG and age. (100) 
 
 The mean levels of OPG correlated with the glucose concentrations in the 
diabetics and diabetics with MI (Table 3).  OPG and glucose have a statistically 
significant linear relationship (p <0.001) in all the groups. The direction of the 
relationship is positive which means they are positively correlated. These 
variables tend to increase together (i.e. greater levels of OPG are integrated with 
higher levels of glucose). In diabetes, with regards to an existing inflammation 
(hyperglycaemia), arterial stiffening and endothelial damage results in intimal 
thickening and development of intimal calcification. This calcification has shown 
to be due to the imbalance between the osteoclastic differentiation and increased 
osteoblastic activity mediated by the OPG/RANKL pathway which subsequently 
results in plaque instability and rupture causing myocardial ischemia.(2,3,65,94) 
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 A receiver operating characteristics (ROC) curve was obtained for OPG for 
the diagnosis of diabetes. The area under the ROC curve was 0.900 with a 
sensitivity of 91.5% and specificity of 94.3%; SE = 0.043 and a confidence 
interval from 0.815 to 0.985.  The cut-off value of OPG for the diagnosis of 
diabetes was 11ng/mL. 
 
 An ROC curve of OPG was acquired for the diagnosis of diabetes with MI. 
The area under the ROC curve is 0.98 for the diagnosis of MI with a good 
sensitivity and specificity (sensitivity =93.4%, specificity = 97.6%), SE = 0.017 
and confidence interval from 0.942 to 1.009. The cut-off value of OPG for the 
diagnosis of diabetes with MI was 12ng/mL. Thus, the ROC curve analysis 
showed that plasma OPG levels are better predictors of cardiovascular risks  
(AUC = 0.98, p < 0.001). 
 
 The relationship of OPG was evaluated with factors like total 
cholesterol, LDL and HDL cholesterol levels. OPG correlated positively with 
total and LDL cholesterol in patients with diabetes with MI. These variables 
tend to increase together. It had a negative correlation with HDL cholesterol; 
higher levels of OPG were associated with lower levels of HDL-C. Recently, it 
has been found that adiponectin contributes a part for the pro-inflammatory 
milieu.(101) Among the large number of adipokines, adiponectin appears to be 
decreased in patients with CAD. Hotta et al. found that still lower levels of 
adiponectin were observed in type 2 diabetics with CAD, which might have 
contributed to the increased LDL and decreased HDL-C levels.(102) 
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 The OPG levels were correlated with biomarker of myocardial ischemia 
like CK-MB. OPG positively correlated with this marker in group 3 patients 
(diabetics with MI). Hence it is proved that OPG can be used as an independent 
predictor of MI in asymptomatic diabetic patients. This was also observed in 
the study by Avignon et al.(96) 
 
 Furthermore, increased plasma OPG associated with peripheral arterial 
disease in type 2 diabetes was noted by Moreno et al. Higher OPG levels were 
accompanied by microvascular complications like nephropathy, neuropathy 
and retinopathy.(78) Many studies demonstrate an elevated OPG levels in 
endothelial dysfunction associated with type 1 diabetes which may predispose 
them to early atherosclerosis.(103) Distinguished OPG levels were observed in 
patients with higher prospect of 10-year cardiovascular risk.(97) Reinhard et al. 
in their prospective observational study identified that high levels of OPG was 
a strong predictor of all-cause mortality. 
  
Conclusion 
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CONCLUSION 
 
1. A high plasma OPG level is associated with an increased risk for 
myocardial infarction in type 2 diabetes mellitus. 
2. OPG can be used for assessing the risk of myocardial infarction. 
3. OPG can also be used to determine the outcome of complications oftype 2 
diabetes mellitus. 
 
  
Limitations of the Study 
  
78 
 
 
 
LIMITATIONS OF THE STUDY 
 
1. The study group is smaller and has to be confirmed in a larger population. 
2. The association of OPG with the duration of diabetes has to be studied. 
3. The effect of anti-diabetic drugs on OPG has to be studied. 
4. The calcification could have been assessed by coronary artery calcification 
(CAC) score or diagnostic coronary angiography to take up the cudgels for 
elevated OPG levels. 
 
  
Future Prospects of the study 
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FUTURE PROSPECTS OF THE STUDY 
 
1. A study on the difference in the ethnicity and genetic stock can be 
elucidated in a larger study on the Indian population. 
2. A more relevant study would be a genetic approach to investigate the OPG 
gene polymorphism which would enable to identify the people at risk for 
coronary artery disease in India. 
3. The role of exogenous insulin on the expression of OPG/ RANKL in the 
vascular calcified cells, in a dose and time dependent manner on a long 
term to control the progression and development of tissue damage can be 
studied. 
4. A prospective study may be conducted on normo-glycaemic people with 
increased OPG, to test its predictive value as an independent risk factor. 
5. Future studies to explain if OPG levels would be informative for a 
biomarker-guided therapy in type 2 diabetic individuals with or without 
known cardiovascular disease. 
6. If OPG could be used as a target of therapy in type 2 diabetes mellitus 
patients to control the microvascular and macrovascular complications 
should be studied.  
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